Sophia Genetics
- hard tech
- biotechnology
- analytics
- core ai
- spinout
- ai applications
- data analytics
- verified unicorns and $1b exits
- genetics
- dna
- genome engineering
- drug development
- tech for hospitals & clinics
- tech for medical professionals
- knowledge management
- insurtech related
- digital pharma
- clinical decision support
- precision medicine
- medical imaging
- from $1b exit to zebra
- techscale200
Financials
Estimates*
EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 25.8m | 36.8m | 43.2m | 56.7m | 59.9m | 72.4m | 92.5m |
% growth | 12 % | 42 % | 18 % | 31 % | 6 % | 21 % | 28 % |
EBITDA | (31.5m) | (61.7m) | (74.8m) | (56.3m) | (51.2m) | (42.5m) | (34.7m) |
% EBITDA margin | (122 %) | (168 %) | (173 %) | (99 %) | (85 %) | (59 %) | (38 %) |
Profit | (35.8m) | (67.0m) | (79.5m) | (71.8m) | (54.7m) | (52.2m) | (44.7m) |
% profit margin | (139 %) | (182 %) | (184 %) | (127 %) | (91 %) | (72 %) | (48 %) |
EV / revenue | - | 15.7x | -0.6x | 2.9x | 3.1x | 3.1x | 2.6x |
EV / EBITDA | - | -9.4x | 0.3x | -3.0x | -3.6x | -5.3x | -6.9x |
R&D budget | 16.9m | 24.2m | 32.2m | 33.6m | - | - | - |
R&D % of revenue | 65 % | 66 % | 74 % | 59 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Seed | ||
* | N/A | Spinout | |
CHF100k | Debt | ||
N/A | Seed | ||
N/A | CHF3.8m | Series A | |
$13.8m | Series B | ||
$15.0m | Series C | ||
* | $30.0m | Series D | |
€67.0m | Series E | ||
$110m | Series F | ||
N/A | $234m Valuation: $1.1b 40.1x EV/LTM Revenues -32.9x EV/LTM EBITDA | IPO | |
* | $50.0m | Post IPO Debt | |
Total Funding | €224m |
Related Content
Recent News about Sophia Genetics
EditSophia Genetics is a healthcare analytics startup that operates in the field of data-driven medicine. The company's primary offering is the SOPHiA DDM™ Platform, a cloud-based system powered by artificial intelligence (AI) and machine learning (ML). This platform allows healthcare providers to standardize, compute, and analyze digital health data, generating insights that can improve diagnosis, therapy selection, analysis, and drug development.
Sophia Genetics serves a wide range of customers, including hospitals, research institutions, and pharmaceutical companies. These customers perform testing on their own samples, retain ownership of their data, and use the SOPHiA DDM™ Platform to analyze this data. They can also share their insights with each other, contributing to a collective intelligence that can improve patient outcomes worldwide.
The company operates in a global market, with a particular focus on genomic profiling. This involves analyzing a patient's genetic information to understand their susceptibility to certain diseases, such as cancer or inherited disorders. The SOPHiA DDM™ Platform can analyze complex multimodal data sets, which means it can handle different types of data at the same time.
Sophia Genetics makes money by charging its customers for access to the SOPHiA DDM™ Platform. This business model allows the company to generate revenue while also contributing to the democratization of data-driven medicine.
Keywords: Healthcare Analytics, Data-Driven Medicine, Genomic Profiling, Artificial Intelligence, Machine Learning, Cloud-Based Platform, Digital Health Data, Collective Intelligence, Global Market, Business Model.